Food and Drug Administration (FDA) approval in May 2022 for the treatment of type 2 diabetes
DDR2 facilitates papillary thyroid carcinoma epithelial-mesenchymal transition by activating ERK2/Snail1 pathway
These medications: reduce appetite lower inflammation improve liver fat improve metabolic markers reduce cardiovascular events (SELECT trial) They do not : build muscle increase VO max improve mitochondrial function replace strength training fix metabolic flexibility guarantee long-term weight maintenance 2
What if Im a non-responder
Retatrutide has not yet reached this stage of regulatory submission in the UK
Clinical Benefits: Supports cellular energy production via the Krebs cycle and mitochondrial function Assists in the metabolism of carbohydrates, fats, and proteins Supports peripheral and central nervous system function Provides antioxidant protection against oxidative stress Supports immune function and recovery from illness May help address fatigue, low mood, and cognitive difficulties This combination is often recommended as part of a broader treatment plan for patients with chronic fatigue, nutritional deficiencies, or those who are not responding adequately to oral supplementation alone